ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo

ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo

Neuroblastoma (NB) is a pediatric tumor of the peripheral nervous system. Approximately 80% of relapsed NB show RAS-MAPK pathway mutations that activate ERK, resulting in the promotion of cell proliferation and drug resistance. Ulixertinib, a first-in-class ERK-specific inhibitor, has shown promisin...

Full description

Bibliographic Details
Main Authors: Yang Yu, Yanling Zhao, Jongmin Choi, Zhongcheng Shi, Linjie Guo, John Elizarraras, Andy Gu, Feng Cheng, Yanxin Pei, Dai Lu, Muller Fabbri, Saurabh Agarwal, Chunchao Zhang, Sung Yun Jung, Jennifer H. Foster, Jianhua Yang
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
neuroblastoma
ulixertinib
ERK inhibition
combination therapy
c-Myc/N-Myc
Online Access:https://www.mdpi.com/2072-6694/14/22/5534

Internet

https://www.mdpi.com/2072-6694/14/22/5534

Similar Items